Last reviewed · How we verify
MB02-SP
At a glance
| Generic name | MB02-SP |
|---|---|
| Also known as | MB02-SP (Bevacizumab Biosimilar) |
| Sponsor | mAbxience Research S.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB02-SP CI brief — competitive landscape report
- MB02-SP updates RSS · CI watch RSS
- mAbxience Research S.L. portfolio CI